Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- Test how well the study medicine Abemaciclib, a CDK4/6 inhibitor, works to shrink lung
cancer tumors in the body.
- Test the safety of Abemaciclib when given to participants with small cell lung cancer
(SCLC). Specifically, this study is looking at SCLC that has not responded to treatment
(refractory) or come back after treatment with chemotherapy (relapsed) as the study
medication has been shown to be effective any time the disease relapses not just in the
first few months.